2-(t-butyloxycarbonylamino)-3-phenylpropyl methanesulfonate | 134807-64-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(t-butyloxycarbonylamino)-3-phenylpropyl methanesulfonate
• 英文别名: 2-[(tert-Butoxycarbonyl)amino]-3-phenylpropyl methanesulfonate；[2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropyl] methanesulfonate
• CAS: 134807-64-0
• 化学式: C₁₅H₂₃NO₅S
• 分子量: 329.417
• InChiKey: CIRITGBVSKUMAF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  90.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(t-butyloxycarbonylamino)-3-phenylpropyl methanesulfonate 在 盐酸 、 sodium azide 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 反应 4.5h， 生成 2-azido-1-benzylethylamine
  参考文献：
  名称：

  通过Ugi / Staudinger / aza-Wittig序列合成取代的咪唑啉

  摘要：

  由Ugi-4CR–Staudinger–aza-Wittig-序列从简单的叠氮基烷基胺开始制备了具有5个多样性点的一系列2-（乙酰胺-2-基）-咪唑啉（II）。Ugi产品（I）的亚氨基膦与叔酰胺之间的分子内氮杂-维蒂希环化反应是通过短波微波辐射进行的。与仲酰胺的竞争性环化无关紧要，但是，在某些情况下，观察到随后形成了双环邻位am（III）。

  DOI：

  10.1016/j.tetlet.2015.01.043
• 作为产物：
  描述：

  N-甲基-N-叔丁氧羰基-D-苯丙氨酸 在 吡啶 、 lithium aluminium tetrahydride 、 potassium hydrogencarbonate 作用下， 生成 2-(t-butyloxycarbonylamino)-3-phenylpropyl methanesulfonate
  参考文献：
  名称：

  Structure–activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region

  摘要：

  Ritonavir (RTV), an HIV-1 protease inhibitor (PI), is also a potent mechanism-based inhibitor of human cytochrome P450 3A (CYP3A) and has been widely prescribed as a pharmacoenhancer. As a boosting agent for marketed PIs, it reduces pill burden, and improves compliance. Removal of the hydroxyl group from RTV reduces, but does not eliminate HIV PI activity and does not affect CYP3A inhibition. Herein we report the discovery of a novel series of CYP3A inhibitors that are devoid of antiviral activity. The synthesis and evaluation of analogs with extensive modifications of the 1,4-diamine core along with the structure activity relationships with respect to anti-HIV activity, CYP3A inhibitory activity, selectivity against other CYP enzymes and the human pregnane X receptor (PXR) will be discussed. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.058

文献信息

• [EN] HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS<br/>[FR] COMPOSÉS D'AMINOPYRIDINE SUBSTITUÉS PAR HÉTÉROARYLE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2016210034A1

  公开（公告）日：2016-12-29

  Disclosed are compounds of Formula (I) or salts thereof, wherein HET is a heteroaryl selected from pyrrolo[2,3 b]pyridinyl, pyrrolo[2,3 d]pyrimidinyl, pyrazolo[3,4 b]pyridinyl, pyrazolo[3,4 d]pyrimidinyl, imidazolo[4,5 b]pyridinyl, and imidazolo[4,5 d]pyrimidinyl, wherein said heteroaryl is attached to the pyridinyl group in the compound of Formula (I) by a nitrogen ring atom in said heteroaryl and wherein said heteroaryl is substituted with zero to 2 Rb; A is pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxadiazolyl or dihydroisoxazolyl, each substituted with zero or 1 Ra; and R3, Ra, and Rb are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

  公开的是Formula (I)的化合物或其盐，其中HET是从吡咯并[2,3 b]吡啶基、吡咯并[2,3 d]嘧啶基、吡唑并[3,4 b]吡啶基、吡唑并[3,4 d]嘧啶基、咪唑并[4,5 b]吡啶基和咪唑并[4,5 d]嘧啶基中选择的杂芳基，其中所述杂芳基通过所述杂芳基中的一个氮环原子连接到Formula (I)的化合物中的吡啶基，并且所述杂芳基被取代为零至2个Rb；A是吡唑基、咪唑基、三唑基、异噁唑基、噁二唑基或二氢异噁唑基，每个取代为零或1个Ra；R3、Ra和Rb在此处定义。还公开了使用这些化合物作为IRAK4调节剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓炎症和自身免疫疾病，或在癌症治疗中是有用的。
• [EN] 4-ARYL-BUTANE-1,3-DIAMIDES<br/>[FR] 4-ARYL-BUTANE-1,3-DIAMIDES
  申请人：NOVARTIS AG

  公开号：WO2011073316A1

  公开（公告）日：2011-06-23

  The invention relates to compound of the formula (I): in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.

  这项发明涉及以下式(I)的化合物：其中取代基如规范中所定义；以自由形式或盐形式存在；其制备方法，其作为药物的用途以及包含它的药物。
• Novel compounds that are useful for improving pharmacokinetics
  申请人：Kempf J. Dale

  公开号：US20060199851A1

  公开（公告）日：2006-09-07

  Novel compounds of formula 1 or a pharmaceutically acceptable salt thereof inhibit cytochrome P450 monooxygenase.

  公式1的新化合物或其药用可接受的盐可以抑制细胞色素P450单加氧酶。
• Retroviral protease inhibiting compounds
  申请人：Abbott Laboratories

  公开号：US05142056A1

  公开（公告）日：1992-08-25

  A retroviral protease inhibiting compound of the formula A--X--B or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein X is a linking group; A is (1) substituted amino, (2) substituted carbonyl, (3) functionalized imino, (4) functionalized alkyl, (5) functionalized acyl, (6) functionalized heterocyclic or (7) functionalized (heterocyclic)alkyl; and B is (1) substituted carbonyl independently defined as herein, (2) substituted amino independently defined as herein, (3) functionalized imino independently defined as herein, (4) functionalized alkyl independently defined as herein, (5) functionalized acyl independently defined as herein, (6) functionalized heterocyclic independently defined as herein or (7) functionalized (heterocyclic)alkyl independently defined as herein.

  一种抑制逆转录病毒蛋白酶的化合物，其化学式为A--X--B或其药用盐、前药或酯，其中X为连接基；A为（1）取代氨基，（2）取代羰基，（3）官能化亚胺基，（4）官能化烷基，（5）官能化酰基，（6）官能化杂环基或（7）官能化（杂环）烷基；B为（1）取代羰基，独立定义如本文所述，（2）取代氨基，独立定义如本文所述，（3）官能化亚胺基，独立定义如本文所述，（4）官能化烷基，独立定义如本文所述，（5）官能化酰基，独立定义如本文所述，（6）官能化杂环基，独立定义如本文所述或（7）官能化（杂环）烷基，独立定义如本文所述。
• The Discovery of New Human Coagulation Factor XIa (FXIa) Inhibitors by Synthesis, Biological Evaluation, and Structure-based Modeling
  作者：Myeong Hwi Lee、Ho Young Song、Hyoungrae Kim、Kyung Eun Park、Jinyeong Kim、Tae Kyo Park、Yong Ju Kim、Nam Sook Kang

  DOI：10.1002/bkcs.10831

  日期：2016.7

  Factor XIa (FXIa) is an enzyme that is activated during the earliest stage of initiation of the intrinsic pathway of the blood coagulation mechanism. In this study, we attempted to discover a new FXIa inhibitor based on structure‐based molecular modeling. We found that compound 16 exhibits satisfactory predicted properties while maintaining important binding interactions with FX1a.

  XIa因子（FXIa）是一种在凝血机制内在途径起始的最早阶段被激活的酶。在这项研究中，我们试图基于基于结构的分子模型发现一种新的FXIa抑制剂。我们发现化合物16表现出令人满意的预测特性，同时保持与FX1a的重要结合相互作用。